The changing epidemiology of non-valvular atrial fibrillation: The role of novel risk factors

European Heart Journal, Supplement

Volumn 7, Issue C, 2005, Pages

  Gersh, Bernard J ^a   Tsang, Teresa S M ^a   Barnes, Marion E ^a   Seward, James B ^a  

^a Mayo Clinic   (United States)

Author keywords

Atrial fibrillation; Epidemiology; Genetics; Risk factors

Indexed keywords

AGE; AGING; ATHEROSCLEROSIS; BLOOD VESSEL COMPLIANCE; CONGESTIVE HEART FAILURE; ENVIRONMENTAL FACTOR; EPIDEMIC; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; INFLAMMATION; METABOLIC SYNDROME X; MOLECULAR GENETICS; MORBIDITY; MORTALITY; OBESITY; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SOCIOECONOMICS; STROKE; THROMBOEMBOLISM;

EID: 18744408148     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/sui014     Document Type: Review

References (64)

1. Silverman M. From rebellious palpitations to the discovery of auricular fibrillation: contributions of Mackenzie, Lewis, and Einthoven. Am J Cardiol 1994;73:384-389.
2. Tsang T, Gersh BJ. Atrial fibrillation: an old disease, a new epidemic. Am J Cardiol 2002;113:432-435.
3. Chugh SS, Blackshear JL, Shen WK et al. Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol 2001;37:371-378.
4. Feinberg WM, Blackshear JL, Laupacis A et al. Prevalence, age distribution and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med 1995;155:469-473.
5. Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation 2003;108:711-716.
6. Stewart S, Murphy N, Walker A et al. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 2004;90:286-292.
7. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-988.
8. Braunwald E. Shattuck lecture-cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 1997;337:1360-1369.
9. Wang TJ, Larson MG, Levy D et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003;107:2920-2925.
10. Gersh BJ, Tsang TSM, Seward JB. The changing epidemiology and natural history of nonvalvular atrial fibrillation: clinical implications. Trans Am Clin Climatol Assoc 2004;114:149-160.
11. Wolf PA, Benjamin EJ, Belanger AJ et al. Secular trends in the prevalence of atrial fibrillation: the Framingham Study. Am Heart J 1996;131:790-795.
12. Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults. National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-2375.
13. Furberg C, Psaty BM, Manolio TA et al. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994;74:236-241.
14. Blackshear JL, Kopecky SL, Litin SC et al. Management of atrial fibrillation in adults: prevention of thromboembolism and symptomatic treatment. Mayo Clin Proc 1996;71:150-160.
15. Page RL, Wilkinson WE, Clair WK et al. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 1994;89:224-227.
16. Israel CW, Gronefeld G, Ehrlich JR et al. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care. J Am Coll Cardiol 2004;43:47-52.
17. Tsang TS, Petty GW, Barnes ME et al. The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota: changes over three decades. J Am Coll Cardiol 2003;42:93-100.
18. Kannel WB, Abbott RD, Savage DD et al. Epidemiology features of chronic atrial fibrillation: the Framingham Study. N Engl J Med 1982;306:1018-1022.
19. Gillum R. Trends in acute myocardial infarction and coronary heart disease death in the United States. J Am Coll Cardiol 1994;23:1273-1277.
20. McGovern PG, Jacobs DR Jr, Shahar E et al. Trends in acute coronary heart disease mortality, morbidity, and medical care from 1985 through 1997: the Minnesota Heart Survey. Circulation 2001;104:19-24.
21. Benjamin EJ, Levy D, Vaziri SM et al. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. JAMA 1994;271:840-844.
22. Chung MK, Martin DO, Sprecher D et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001;104:2886-2891.
23. Dernellis J, Panaretou M. C-reactive protein and paroxysmal atrial fibrillation: evidence of the implications of an inflammatory process in paroxysmal atrial fibrillation. Acta Cardiol 2001;56:375-380.
24. Ridker PM, Rifai N, Clearfield M et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-1965.
25. Tsang TS, Barnes ME, Gersh BJ et al. Prediction of risk for first age-related cardiovascular events in an elderly population: the incremental value of echocardiogram. J Am Coll Cardiol 2003;42:1199-1205.
26. Quan SF, Gersh BJ. Consequences of sleep-disordered breathing: past, present, and future: report of a workshop from the National Center on Sleep Disorders Research and the National Heart, Lung, and Blood Institute. Circulation 2004;109:951-957.
27. Shamsuzzaman AS, Gersh BJ, Somers VK. Obstructive sleep apnea: implications for cardiac and vascular disease. JAMA 2003;290:1906-1914.
28. Krahn AD, Manfreda J, Tate RB et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995;98:476-484.
29. Ruigomez A, Johansson S, Wallander MA et al. Incidence of chronic atrial fibrillation in general practice and its treatment pattern. J Clin Epidemiol 2002;55:358-363.
30. Stewart S, Hart CL, Hole DJ et al. Population prevalence, incidence, and predictions of atrial fibrillation in the Renfrew/Paisley Study. Heart 2001;86:516-521.
31. Kannel WB, Wolf PA, Benjamin EJ et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82:2N-9N.
32. Tamakoshi K, Yatsuya H, Kondo T et al. The metabolic syndrome is associated with elevated circulating C-reactive protein in healthy reference range, a systemic low-grade inflammatory state. Int J Obes Relat Metab Disord 2003;27:443-449.
33. Frohlich M, Imhof A, Berg G et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 2000;23:1835-1839.
34. Barnes ME, Miyasaka Y, Rosales AG et al. Obesity as an independent predictor of first atrial fibrillation in adults aged greater than or equal to 65 years. (Abstract 885). J Am Coll Cardiol 2004;43:240A.
35. Ujino K, Miyasaka Y, Barnes ME et al. Obesity: an independent predictor of diastolic dysfunction in men and women aged 65 years and older. J Am Soc Ecnocardiogr 2003;16:560.
36. Young T, Shahar E, Nieto FJ et al. Predictors of sleep-disordered breathing in community dwelling adults: the Sleep Heart Health Study. Arch Intern Med 2002;162:893-900.
37. Young T, Palta M, Dempsey J et al. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993;328:1230-1235.
38. Redline S. Epidemiology of sleep-disordered breathing. Sem Resp Crit Care M 1998;19:113-122.
39. Kanagala R, Murali NS, Friedman PA et al. Obstructive sleep apnea and the recurrence of atrial fibrillation. Circulation 2003;107:2589-2594.
40. Gami AS, Pressman G, Caples SM et al. Association of atrial fibrillation and obstructive sleep apnea. Circulation 2004;110:364-367.
41. Krieger J, Laks L, Wilcox I et al. Atrial natriuretic peptide release during sleep in patients with obstructive sleep apnoea before and during treatment with nasal continuous positive airway pressure. Clin Sci (Lond) 1989;77:407-411.
42. Edwards BS, Zimmerman RS, Schwab TR et al. Atrial stretch, not pressure, is the principle determinant controlling the acute release of atrial natriuretic factor. Circ Res 1988;62:191-195.
43. Goksor E, Rosengren L, Wennergren G. Bradycardic response during submersion in infant swimming. Acta Paediatr 2002;91:307-312.
44. Shamsuzzaman AS, Winnicki M, Lanfranchi P et al. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation 2002;105:2462-2464.
45. Redfield MM, Jacobsen SJ, Burnett JC Jr et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003;289:194-202.
46. Tsang TS, Gersh BJ, Appleton CP. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol 2002;40:1636-1644.
47. Bode F, Katchman A, Woosley RL et al. Gadolinium decreases stretch-induced vulnerability to atrial fibrillation. Circulation 2000;101:2200-2205.
48. Tsang TS, Barnes ME, Gersh BJ et al. Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. Am J Cardiol 2002;90:1284-1289.
49. Douglas P. The left atrium: a biomarker of chronic diastolic dysfunction and cardiovascular disease risk. J Am Coll Cardiol 2003;42:1206-1207.
50. Madrid AH, Escobar C, Rebollo JM et al. Angiotensin receptor blocker as adjunctive therapy for rhythm control in atrial fibrillation: results of the irbesartan-amiodarone trial. Card Electrophysiol Rev 2003;7:243-246.
51. Pedersen OD, Bagger H, Kober L et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999;100:376-380.
52. Vermes E, Tardif JC, Bourassa MG. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies of Left Ventricular Dysfunction (SOLVD) Trials. Circulation 2003;107:2926-2931.
53. Kumagai K, Nakashima H, Urata H et al. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003;41:2197-2204.
54. Klein HU, Goette A. Blockade of atrial angiotensin II type 1 receptors: a novel antiarrhythmic strategy to prevent atrial fibrillation? J Am Coll Cardiol 2003;41:2205-2206.
55. Pedersen OD, Kober L, Torp-Pedersen C. Atrial fibrillation and atrial cardiomyopathy: two sides of the same coin? Am Heart J 2004;147:953-955.
56. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized, controlled trials. Arch Intern Med 1994;154:1449-1457.
57. Kopecky SL, Gersh BJ, McGoon MD et al. The natural history of lone atrial fibrillation. A population-based study over three decades. N Engl J Med 1987;317:669-674.
58. SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. JAMA 1998;279:1273-1277.
59. Brugada R, Roberts R. Molecular biology and atrial fibrillation. Curr Opin Cardiol 1999;14:269-273.
60. Darbar D, Herron KJ, Ballew JD et al. Familial atrial fibrillation is a genetically heterogeneous disorder. J Am Coll Cardiol 2003;41:2185-2192.
61. Chen YH, Xu SJ, Bendahhou S. KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science 2003;299:251-254.
62. Mestroni L. Genomic medicine in atrial fibrillation. J Am Coll Cardiol 2003;41:2193-2196.
63. Ellinor PT, Shin JT, Moore RK et al. Locus for atrial fibrillation maps to chromosome 6q14-16. Circulation 2003;107:2880-2883.
64. Roberts R, Brugada R. Genetic aspects of arrhythmias. Am J Med Genet 2000;97:310-318.